| Inhibition of mutated, activated BRAF in metastatic melanoma KT Flaherty, I Puzanov, KB Kim, A Ribas, GA McArthur, JA Sosman, ... New England Journal of Medicine 363 (9), 809-819, 2010 | 4290 | 2010 |
| Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline JR Brahmer, C Lacchetti, BJ Schneider, MB Atkins, KJ Brassil, ... Journal of Clinical Oncology 36 (17), 1714-1768, 2018 | 3551 | 2018 |
| Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations KT Flaherty, JR Infante, A Daud, R Gonzalez, RF Kefford, J Sosman, ... New England Journal of Medicine 367 (18), 1694-1703, 2012 | 3128 | 2012 |
| Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab SL Topalian, M Sznol, DF McDermott, HM Kluger, RD Carvajal, ... Journal of clinical oncology 32 (10), 1020-1030, 2014 | 2693 | 2014 |
| Talimogene laherparepvec improves durable response rate in patients with advanced melanoma RHI Andtbacka, HL Kaufman, F Collichio, T Amatruda, N Senzer, ... Journal of clinical oncology 33 (25), 2780-2788, 2015 | 2629 | 2015 |
| Survival in BRAF V600–mutant advanced melanoma treated with vemurafenib JA Sosman, KB Kim, L Schuchter, R Gonzalez, AC Pavlick, JS Weber, ... New England Journal of Medicine 366 (8), 707-714, 2012 | 2595 | 2012 |
| Fulminant myocarditis with combination immune checkpoint blockade DB Johnson, JM Balko, ML Compton, S Chalkias, J Gorham, Y Xu, ... New England Journal of Medicine 375 (18), 1749-1755, 2016 | 2044 | 2016 |
| Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma G Bollag, P Hirth, J Tsai, J Zhang, PN Ibrahim, H Cho, W Spevak, C Zhang, ... Nature 467 (7315), 596-599, 2010 | 2042 | 2010 |
| Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations DM Hyman, I Puzanov, V Subbiah, JE Faris, I Chau, JY Blay, J Wolf, ... New England Journal of Medicine 373 (8), 726-736, 2015 | 1882 | 2015 |
| Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial A Ribas, I Puzanov, R Dummer, D Schadendorf, O Hamid, C Robert, ... The lancet oncology 16 (8), 908-918, 2015 | 1765 | 2015 |
| Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group I Puzanov, A Diab, K Abdallah, CO Bingham, C Brogdon, R Dadu, ... Journal for immunotherapy of cancer 5, 1-28, 2017 | 1728 | 2017 |
| Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy A Ribas, R Dummer, I Puzanov, A VanderWalde, RHI Andtbacka, ... Cell 170 (6), 1109-1119. e10, 2017 | 1274 | 2017 |
| RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors F Su, A Viros, C Milagre, K Trunzer, G Bollag, O Spleiss, JS Reis-Filho, ... New England Journal of Medicine 366 (3), 207-215, 2012 | 1204 | 2012 |
| Combined nivolumab and ipilimumab in melanoma metastatic to the brain HA Tawbi, PA Forsyth, A Algazi, O Hamid, FS Hodi, SJ Moschos, ... New England Journal of Medicine 379 (8), 722-730, 2018 | 1202 | 2018 |
| Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial K Margolin, MS Ernstoff, O Hamid, D Lawrence, D McDermott, I Puzanov, ... The lancet oncology 13 (5), 459-465, 2012 | 1200 | 2012 |
| Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial GV Long, U Trefzer, MA Davies, RF Kefford, PA Ascierto, PB Chapman, ... The lancet oncology 13 (11), 1087-1095, 2012 | 1025 | 2012 |
| Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial NB Haas, J Manola, RG Uzzo, KT Flaherty, CG Wood, C Kane, M Jewett, ... The Lancet 387 (10032), 2008-2016, 2016 | 662 | 2016 |
| Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders DB Johnson, RJ Sullivan, PA Ott, MS Carlino, NI Khushalani, F Ye, ... JAMA oncology 2 (2), 234-240, 2016 | 629 | 2016 |
| Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with … J Chesney, I Puzanov, F Collichio, P Singh, MM Milhem, J Glaspy, ... Journal of Clinical Oncology 36 (17), 1658-1667, 2018 | 587 | 2018 |
| Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma I Puzanov, MM Milhem, D Minor, O Hamid, A Li, L Chen, M Chastain, ... Journal of Clinical Oncology 34 (22), 2619-2626, 2016 | 547 | 2016 |
